Frontline Shifts: Are We Seeing a New Standard of Care in GI Oncology? Ep 01.

In this inaugural episode of The Gut Onc Lab, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal sit down to break down the most impactful data from the 2026 ASCO GI Cancers Symposium. From bispecific antibodies in upper GI to the long-awaited "drugging" of KRAS in pancreatic cancer, the team discusses how these latest clinical findings are ready to move from the podium to the clinic.   Key highlights include: Upper GI Advances: A deep dive into the HERIZON-GEA-01 trial and whether the zanidatamab triplet (Zani + Tislelizumab + Chemo) is ready to replace the current standard of care. Claudin 18.2 Synergy: Early signals from the ILUSTRO trial combining zolbetuximab and nivolumab, and the practical challenges of managing infusion toxicities. Pancreatic Cancer Breakthroughs: The "wild" 37% response rate of oral KRAS G12D inhibitors (INCB161734) in heavily pre-treated patients. Whether you are a seasoned practitioner or a trainee, join the collab for a candid look at the "latest and greatest" in GI medical oncology.   Chapters: (00:00) ASCO GI 2026 Kickoff (02:31) HORIZON GEA HER2 Data (04:23) Zanidatamab Practical Takeaways (08:04) Claudin 18.2 Combo Signals (10:13) Managing Zolbetuximab Toxicity (11:45) Pancreatic KRAS G12D Breakthrough (15:26) Breakwater Updates in BRAF CRC (17:58) FOLFOX vs FOLFIRI Debate (20:52) Closing Thoughts and Sign Off